

Certificate of Transmission by Mailing, Facsimile, or Electronic Transmission (37 C.F.R. §1.8)	
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is:	
<input type="checkbox"/> being deposited with the U.S. Postal Service on the date indicated below and with sufficient postage addressed to Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.	
<input type="checkbox"/> being facsimile transmitted to the Commissioner for Patents, U.S.P.T.O. (Fax No. 571-273-8300) on the date indicated below.	
<input checked="" type="checkbox"/> being transmitted to the Commissioner for Patents via the U.S.P.T.O. Electronic Filing System on the date indicated below.	
Signature: /Gary R. Fabian/ Reg. No. 33,875	Date: 3 February 2010

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE	
In Re Application of: Stanford Mark Moran	Confirmation No. 8022
Serial No.: 10/004,118	Art Unit: 1647
Filing Date: 30 October 2001	Examiner: Seharaseyon, J.
Title: METHOD FOR TREATING DISEASES WITH OMEGA INTERFERON	

TRANSMITTAL

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing in the above-referenced application are the following documents:

1. Transmittal;
2. Response to Rejection, including complete listing of the claims;
3. Petition For Extension Of Time Under 37 CFR 1.136(a), including authorization to charge Deposit Account the required fee;
4. Request for Continued Examination (RCE), including authorization to charge Deposit Account the required fee; and
5. Certificates of Transmission.

I. Request for Continued Examination (RCE)

A Request for Continued Examination (RCE) accompanies this paper. The RCE is being filed after filing of a Notice of Appeal but before filing of the Appeal Brief. Accordingly, Applicant requests that the filing of the RCE is treated as a request to withdraw the appeal and to reopen prosecution of the application before the Examiner (*see* 37 C.F.R. §1.114).

II. Authorization to Charge Deposit Account

No additional fees are believed due in connection with this paper. However, the Commissioner is hereby authorized to charge to Deposit Account No. **504212** any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, with the exception of the payment of the Issue Fee.

Address all future communications to **Customer Number: 000074866**

Barbara G. McClung, Esq.
Vice President, General Counsel and Corporate Secretary
Intarcia Therapeutics, Inc.
24650 Industrial Blvd
Hayward CA 94545
Phone: 510-782-7800 ext 122
Facsimile: 510-782-7801

Respectfully submitted,

Date: 3 February 2010

By: /Gary R. Fabian/

Gary R. Fabian, Ph.D.
Registration No. 33,875
Agent for Applicants